TY  - BOOK
AU  - Krentz,Andrew J.
AU  - Heinemann,Lutz
AU  - Hompesch,Marcus
ED  - SpringerLink (Online service)
TI  - Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development: A Focus on Early Phase Clinical Studies 
SN  - 9781447149200
AV  - R1 
U1  - 610 23
PY  - 2015///
CY  - London
PB  - Springer London, Imprint: Springer
KW  - medicine
KW  - pharmacology
KW  - Pharmaceutical technology
KW  - Internal medicine
KW  - Diabetes
KW  - Metabolic diseases
KW  - Medicine & Public Health
KW  - Medicine/Public Health, general
KW  - Internal Medicine
KW  - Metabolic Diseases
KW  - Pharmacology/Toxicology
KW  - Pharmaceutical Sciences/Technology
N1  - 1. Review of physiology/pathophysiology -- 2. Methods for assessing insulin action in humans -- 3. Assessment of insulin secretion -- 4. Measurement of ectopic fat in liver and muscle using magnetic resonance spectroscopy -- 5. Isotopic tracers for the measurement of metabolic flux -- 6. Measuring food intake in clinical drug development -- 7. Measurement of energy expenditure -- 8. Assessment of body composition -- 9.  Assessment of cardiovascular safety of new diabetes drugs
N2  - This book aims to aid the selection of the most appropriate techniques for use in early phase (1 and 2) clinical studies of new drugs for diabetes, obesity, and related cardiometabolic disease. Clinical research methods for assessing the pharmacokinetics and pharmacodynamics of new diabetes drugs, e.g. the euglycaemic clamp technique, have become well-established in proof-of-mechanism studies; however, selection of the best techniques is by no means straightforward. This book will aid the understanding of the need for new pharmacotherapies for type 1 diabetes, type 2 diabetes, and obesity and the molecular targets of drugs currently in development.  Emerging technologies including the omics disciplines are considered together with practical and ethical issues of early phase clinical trials in subjects with cardiometabolic disorders. Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development  will be of interest to biomedical scientists, pharmacologists, academics involved in metabolic research and clinicians practicing in these specialties
UR  - http://dx.doi.org/10.1007/978-1-4471-4920-0
ER  -